Goldman Sachs analyst Salveen Richter raised the firm’s price target on Biogen (BIIB) to $225 from $197 and keeps a Buy rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $207 from $177 at Mizuho
- Biogen: Buy Rating Raised on Leqembi Commercial Momentum and 2026 Pipeline Catalysts
- Biogen: Balanced Risk/Reward Amid Alzheimer’s and Autoimmune Pipeline Uncertainty Supports Hold Rating
- Biogen price target raised to $180 from $153 at Citi
- Biogen assumed with a Neutral at UBS